MannKind Corp
NASDAQ:MNKD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.25
7.44
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
MannKind Corp
MannKind Corp
Other Equity
MannKind Corp
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MannKind Corp
NASDAQ:MNKD
|
Other Equity
$588k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Equity
-$2.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Equity
$18.4B
|
CAGR 3-Years
526%
|
CAGR 5-Years
175%
|
CAGR 10-Years
61%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Equity
-$336m
|
CAGR 3-Years
25%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Equity
-$22.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Equity
$60.2m
|
CAGR 3-Years
82%
|
CAGR 5-Years
29%
|
CAGR 10-Years
8%
|
|
MannKind Corp
Glance View
MannKind Corp. stands as a fascinating player in the biotech landscape, primarily due to its focus on innovative drug delivery systems that aim to redefine patient experience and therapeutic efficacy. Founded with the intention of creating transformative medicinal solutions, the company is best known for its flagship product, Afrezza, an inhalable form of insulin designed to manage diabetes. This unique delivery method not only enhances the speed at which insulin begins to act within the body, but also offers a discreet and user-friendly alternative to traditional injectable options. Driven by a blend of science and practicality, MannKind's efforts are centered around enhancing quality of life for patients, marking its territory in a niche, yet crucial, segment of the pharmaceutical market. MannKind generates revenue by producing and distributing its highly specialized products, leveraging partnerships with larger pharmaceutical companies to expand its market reach. By optimizing their drug delivery systems, they aim to position themselves competitively, offering solutions that stand out in a crowded industry. Beyond Afrezza, MannKind seeks to harness its proprietary Technosphere technology platform, exploring applications beyond diabetes to potentially treat other conditions. This approach not only broadens their market horizon but also diversifies potential revenue streams, allowing MannKind to maintain a steady course in the volatile currents of the biotech sector. In essence, MannKind's business strategy is a calculated blend of ingenuity and collaboration, with a clear emphasis on meeting unmet medical needs effectively.
See Also
What is MannKind Corp's Other Equity?
Other Equity
588k
USD
Based on the financial report for Sep 30, 2024, MannKind Corp's Other Equity amounts to 588k USD.
What is MannKind Corp's Other Equity growth rate?
Other Equity CAGR 1Y
47%
Over the last year, the Other Equity growth was 47%.
You don't have any saved screeners yet
